Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.
VRTX - Vertex Pharmaceuticals Incorporated
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$549.21
DETAILS
HIGH:
$616.00
LOW:
$350.00
MEDIAN:
$576.00
CONSENSUS:
$549.21
UPSIDE:
16.09%
Stock News
ABN Amro Investment Solutions Grows Holdings in Vertex Pharmaceuticals Incorporated $VRTX
ABN Amro Investment Solutions boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 257.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,216 shares of the pharmaceutical company's stock after buying an additional 49,146 shares during the quarter.
Andra AP fonden Has $10.67 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX
Andra AP fonden cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 33.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,903 shares of the pharmaceutical company's stock after selling 12,037 shares during the quarter. Andra
Amova Asset Management Americas Inc. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Amova Asset Management Americas Inc. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 66.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,115 shares of the pharmaceutical company's stock after selling 4,199 shares during the period. Amova
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.
Boston Common Asset Management LLC Has $7.68 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX
Boston Common Asset Management LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 7.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,205 shares of the pharmaceutical company's stock after purchasing an additional 1,124 shares
Broderick Brian C Purchases 1,454 Shares of Vertex Pharmaceuticals Incorporated $VRTX
Broderick Brian C grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 8.5% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 18,656 shares of the pharmaceutical company's stock after buying an additional 1,454 shares during the period. Vertex Pharmaceuticals makes up about 1.5% of
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual sales potential. The company's business is strong thanks to its dominance in its core market and new launches in other areas.
Assetmark Inc. Has $26.77 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Assetmark Inc. lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 33.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,954 shares of the pharmaceutical company's stock after selling 30,529 shares during the quarter. Assetmark Inc.'s holdings in Vertex
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.
Is This Biotech Stock a Buy Near Its 52-Week High?
Vertex Pharmaceuticals is making clinical and regulatory progress with some promising candidates. The company's most important business is still performing well.
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings. The biotech has taken key steps in recent years to expand into other treatment areas, and efforts have been bearing fruit.
Why Crinetics Stock Soared 99% This Week
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
Nvidia, Vertex Pharmaceuticals And More On CNBC's ‘Final Trades'
On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, named Roundhill Memory ETF (NASDAQ:DRAM) as her final trade.
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideratio.
Price Targets
Vertex Pharmaceuticals price target raised to $585 from $545 at UBS
$585.00
(was $481.70)
UBS
Vertex Pharmaceuticals price target raised to $560 from $542 at Truist
$560.00
(was $479.01)
Truist Financial
Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
$570.00
(was $529.59)
RBC Capital
Vertex Pharmaceuticals price target raised to $350 from $330 at Baird
$350.00
(was $529.59)
Robert W. Baird
Truist Securities Assumes Vertex (VRTX) at Buy
$542.00
(was $435.93)
Danielle Brill
·
Truist Financial
Vertex Pharmaceuticals price target raised to $615 from $607 at Barclays
$615.00
(was $424.36)
Barclays
Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley
$616.00
(was $417.72)
Morgan Stanley
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
$543.00
(was $429.85)
Brian Abrahams
·
RBC Capital
Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein
$572.00
(was $429.85)
Bernstein
Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
$436.00
(was $429.85)
Canaccord Genuity
Vertex Pharmaceuticals price target lowered to $437 from $441 at Canaccord
$437.00
(was $423.24)
Canaccord Genuity
Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley
$612.00
(was $436.89)
Morgan Stanley
Vertex (VRTX) PT Raised to $525 at Truist Securities
$525.00
(was $499.14)
Joon Lee
·
Truist Financial
Jefferies Starts Vertex (VRTX) at Buy
$580.00
(was $496.50)
Akash Tewari
·
Jefferies
Vertex (VRTX) PT Raised to $600 at BMO Capital
$600.00
(was $487.57)
Evan David Seigerman
·
BMO Capital
Vertex Pharmaceuticals price target raised to $441 from $411 at Canaccord
$441.00
(was $491.47)
Canaccord Genuity
Vertex Pharmaceuticals price target raised to $607 from $606 at Barclays
$607.00
(was $491.47)
Eliana Merle
·
Barclays
Vertex Pharmaceuticals price target raised to $591 from $518 at H.C. Wainwright
$591.00
(was $491.47)
Andrew Fein
·
H.C. Wainwright
Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley
$570.00
(was $497.42)
Terence Flynn
·
Morgan Stanley
Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank
$558.00
(was $493.98)
Louise Chen
·
Scotiabank